AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a clinical study titled A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I Pharmacokinetic Comparability Study of Tozorakimab Administered Using an Accessorised Prefilled Syringe (APFS) or an Autoinjector (AI) in Healthy Volunteers. The study aims to compare the pharmacokinetic exposures of a single subcutaneous dose of tozorakimab administered using either an AI or APFS device in healthy participants. This research is significant as it could influence the delivery method of tozorakimab, potentially impacting its efficacy and patient compliance.
The intervention being tested is tozorakimab, a drug administered via two different devices: an Autoinjector (AI) and an Accessorised Prefilled Syringe (APFS). The purpose is to determine which device offers better pharmacokinetic outcomes, which could lead to improved treatment protocols.
The study is designed as a randomized, open-label, parallel-group trial. Participants are randomly assigned to receive tozorakimab through either the AI or APFS device, with no masking involved. The primary purpose is treatment-focused, aiming to establish the most effective delivery method.
The study began on April 7, 2025, with an initial submission date of April 2, 2025. The latest update was submitted on July 7, 2025. These dates are crucial as they indicate the study’s progression and the timeliness of the data being collected.
The market implications of this study are significant for AstraZeneca and its collaborators. A successful outcome could enhance the marketability of tozorakimab, potentially boosting stock performance and investor confidence. In the competitive pharmaceutical landscape, demonstrating superior drug delivery methods can provide a strategic advantage.
The study is currently recruiting, with further details available on the ClinicalTrials portal, confirming its ongoing status.